A detailed history of Ci Private Wealth, LLC transactions in Tg Therapeutics, Inc. stock. As of the latest transaction made, Ci Private Wealth, LLC holds 40,295 shares of TGTX stock, worth $1.25 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
40,295
Previous 40,352 0.14%
Holding current value
$1.25 Million
Previous $1.45 Million 0.21%
% of portfolio
0.0%
Previous 0.0%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2025

Nov 14, 2025

SELL
$26.39 - $39.19 $1,504 - $2,233
-57 Reduced 0.14%
40,295 $1.46 Million
Q2 2025

Sep 26, 2025

SELL
$33.37 - $45.51 $1.35 Million - $1.84 Million
-40,352 Reduced 50.0%
40,352 $1.45 Million
Q2 2025

Aug 15, 2025

BUY
$33.37 - $45.51 $1.33 Million - $1.82 Million
39,987 Added 98.21%
80,704 $2.9 Million
Q1 2025

May 14, 2025

SELL
$27.67 - $42.99 $184,309 - $286,356
-6,661 Reduced 14.06%
40,717 $1.61 Million
Q4 2024

Feb 10, 2025

SELL
$21.31 - $35.09 $752,434 - $1.24 Million
-35,309 Reduced 42.7%
47,378 $1.43 Million
Q3 2024

Nov 12, 2024

SELL
$17.21 - $25.28 $269,663 - $396,112
-15,669 Reduced 15.93%
82,687 $1.93 Million
Q2 2024

Aug 13, 2024

BUY
$13.32 - $19.19 $345,987 - $498,460
25,975 Added 35.89%
98,356 $1.75 Million
Q1 2024

May 09, 2024

SELL
$13.02 - $21.3 $273,420 - $447,300
-21,000 Reduced 22.49%
72,381 $1.1 Million
Q4 2023

Feb 09, 2024

BUY
$6.68 - $18.81 $435,669 - $1.23 Million
65,220 Added 231.6%
93,381 $1.59 Million
Q3 2023

Nov 03, 2023

BUY
$8.36 - $26.5 $86,944 - $275,600
10,400 Added 58.56%
28,161 $235,000
Q2 2023

Aug 10, 2023

BUY
$15.48 - $35.0 $274,940 - $621,635
17,761 New
17,761 $441,000

Others Institutions Holding TGTX

About TG THERAPEUTICS, INC.


  • Ticker TGTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 145,274,000
  • Market Cap $4.5B
  • Description
  • TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its therapeutic product candidates include Ublituximab, an investigational glycoengineered monoclonal antibody for the treatment of B-cell non-hod...
More about TGTX
Track This Portfolio

Track Ci Private Wealth, LLC Portfolio

Follow Ci Private Wealth, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ci Private Wealth, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Ci Private Wealth, LLC with notifications on news.